

Electronic Supplementary Information for

Photocatalytic Traceless C-N Bond Formation/ Cleavage Strategy Enabling (α -Chiral)
Alkyl Aldehydes as Deoxygenative (Chiral) Alkyl Radical Equivalents

Hanyang Bao,^{§a,c} Limeng Zheng,^{§a,c} Qian Liu,^a Mingfeng Han,^a Ya Li,^a Miao Bao,^c Yuanqiang Li,^c

Pucha Yan^c and Yunkui Liu^{*a,b}

^a State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology, College of Chemical Engineering, Zhejiang University of Technology, Hangzhou 310014, P. R. China

Email: ykuiliu@zjut.edu.cn

^b Key Laboratory of Organosilicon Chemistry and Material, Technology of Ministry of Education, Hangzhou Normal University, Hangzhou 311121, P. R. China

^c Raybow (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou 310018, P. R. China

Table of Contents

1. General Information	S3
2. Preparation of Substrates and Photosensitizers	S4
3. General procedures for deoxygenative alkylation/cyclization of 2-biphenylisonitriles with (α -chiral) alkyl aldehydes	S5
3.1. Optimization of reaction conditions for achiral alkyl aldehydes	S5
3.2. Optimization of reaction conditions for acyclic α -chiral amino aldehyde	S7
3.3. Experimental details and characterization of products 4	S7
3.4. 3 mmol-scale synthesis of 4a	S34
4. Mechanistic Studies	S35
4.1. Radical scavenging experiment	S35
4.2. Formation and detection of intermediate 6 when the reaction time was shorten to 4 h	S35
4.3. Probing experiment on possible reaction intermediate	S35
4.4. Detection of byproduct 4a'	S37
4.5. KIE experiment	S37
4.6 Deuterium-labeling experiments	S38
5. References	S39
6. Copies of ^1H and ^{13}C NMR Spectra	S41


1. General Information

Unless otherwise noted, all reactions were carried out in flame-dried reaction vessels with Teflon screw caps under nitrogen. Solvents were purified and dried according to standard methods prior to use. Unless otherwise stated, all reagents were purchased from commercial suppliers and used as received. Flash column chromatography was performed on silica gel (200-300 mesh) with the indicated solvent mixtures. TLC analysis was performed on pre-coated, glass-backed silica gel plates and visualized with UV light, KMnO_4 indicator or phosphomolybdic acid indicator.


Melting points are uncorrected. ^1H NMR spectra were recorded on a spectrometer at 25 °C in CDCl_3 at 400, 500 or 600 MHz, with TMS as internal standard. ^{13}C NMR spectra were recorded on a spectrometer at 25 °C in CDCl_3 at 101, 125 or 150 MHz. Chemical shifts (δ) are expressed in ppm and coupling constants J are given in Hz. The following abbreviations were used to identify the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, dq = doublet of quartets, br = broad and all combinations thereof can be explained by their integral parts. High resolution mass spectra (HR-MS) were obtained on a TOF-MS instrument with EI or ESI source. Optical rotations were determined using a Rudolph Autopol IV polarimeter. HPLC analyses were performed using Agilent 1200 chromatography or Agilent 1260 chromatography.

2. Preparation of Substrates and Photosensitizers.


2-isocyanobiphenyls **1** were synthesized according to the previously reported procedure.¹ All of these compounds are known compounds and their NMR spectra are consistent with the documented data (**1a**², **1b**¹, **1c**², **1d**², **1e**², **1f**², **1g**², **1h**³, **1i**⁴, **1j**⁵, **1k**⁶, **1l**², **1m**², **1n**⁷, **1o**²).




1a




1b




1c




1d




1e




1f




1g




1h




1i




1j




1k




1l



1m



1n




1o

Aldehydes **2a-2g**, **2j** are commercial available.

2h, **2i**, **2k** was prepared via reduction of corresponding Weinreb amide according to the literature⁸ and their analytical data are consistent with the documented data (**2h**⁸, **2i**⁹, **2k**¹⁰).


N-Boc-L-prolinal (**2l**), *N*-Boc-L-valinal (**2m**), *N*-Boc-L-alaninal (**2n**), *N*-Boc-L-phenylalaninal (**2o**), *tert*-butyl (S)-1-formyl-3-methylbutylcarbamate (**2p**), (S)-*tert*-butyl 3-formylpiperidine-1-carboxylate (**2q**) are commercial available.



4CzIPN was prepared according to the literature and its analytical data are consistent with the documented data.¹¹

3. General procedures for deoxygenative alkylation/cyclization of 2-biphenylisonitriles with (α -chiral) alkyl aldehydes


3.1 Optimization of reaction conditions for achiral alkyl aldehydes^[a]




Entry	PS (x mol%)	Amine (3)	1a/2a/3	Solvent	Yield (4a/5) ^[b]
1	PS1 (7.5)	diethylamine (3a)	1/4.5/4.5	1,4-dioxane	36/12 (5a)
2	PS2 (7.5)	diethylamine (3a)	1/4.5/4.5	1,4-dioxane	53/15 (5a)
3	PS3 (7.5)	diethylamine (3a)	1/4.5/4.5	1,4-dioxane	65/21 (5a)

4	Ru(bpy) ₃ Cl ₂ (7.5)	diethylamine (3a)	1/4.5/4.5	1,4-dioxane	23/12 (5a)
5	<i>fac</i> -Ir(ppy) ₃ (7.5)	diethylamine (3a)	1/4.5/4.5	1,4-dioxane	20/trace (5a)
6	PS4 (7.5)	diethylamine (3a)	1/4.5/4.5	1,4-dioxane	0/0 (5a)
7	PS5 (7.5)	diethylamine (3a)	1/4.5/4.5	1,4-dioxane	53/16 (5a)
8	Rose begal (7.5)	diethylamine (3a)	1/4.5/4.5	1,4-dioxane	0/0 (5a)
9	4CzIPN (7.5)	diethylamine (3a)	1/4.5/4.5	1,4-dioxane	75/trace (5a)
10	4CzIPN (5)	diethylamine (3a)	1/4.5/4.5	1,4-dioxane	75/trace (5a)
11	4CZIPN (2.5)	diethylamine (3a)	1/4.5/4.5	1,4-dioxane	61/trace (5a)
12	4CzIPN (5)	dipropylamine (3b)	1/4.5/4.5	1,4-dioxane	82/trace (5b)
13	4CzIPN (5)	pyrrolidine (3c)	1/4.5/4.5	1,4-dioxane	48/trace (5c)
14	4CzIPN (5)	piperidine (3d)	1/4.5/4.5	1,4-dioxane	81/trace (5d)
15	4CzIPN (5)	methyl 2-piperidinecarboxylate (3e)	1/4.5/4.5	1,4-dioxane	81/trace (5e)
16	4CzIPN (5)	hexamethylenimine (3f)	1/4.5/4.5	1,4-dioxane	59/trace (5f)
20	4CzIPN (5)	dipropylamine (3b)	1/3/3	1,4-dioxane	72/trace (5a)
21	4CzIPN (5)	dipropylamine (3b)	1/1.5/1.5	1,4-dioxane	44/trace (5a)
22	4CzIPN (5)	dipropylamine (3b)	1/4.5/4.5	THF	70/trace (5a)
23	4CzIPN (5)	dipropylamine (3b)	1/4.5/4.5	EA	74/trace (5a)
24 ^[c]	4CzIPN (5)	dipropylamine (3b)	1/4.5/4.5	1,4-dioxane	0/0 (5b)
24	--	dipropylamine (3b)	1/4.5/4.5	1,4-dioxane	0/0 (5b)
25	4CzIPN (5)	--	1/4.5/--	1,4-dioxane	0/0 (5b)
26 ^[d]	4CzIPN (5)	dipropylamine (3b)	1/4.5/4.5	1,4-dioxane	61/ trace (5b)

[a] Reaction condition: **1a** (0.2 mmol), **PS** (x mol %), Hantzsch ester (0.24 mmol), propionaldehyde **2a** (0.9 mmol), amine **3** (0.9 mmol) in solvent (5.0 mL), irradiated with 15 W blue LED at 25 °C under nitrogen atmosphere for 14 h unless otherwise noted. [b] Isolated yield. [c] The reaction was carried out in the dark condition. [d] Hantzsch ester (0.5 equiv. based on **1a**) was used.



3.2 Optimization of reaction conditions for acyclic α -chiral amino aldehyde.^[a]



Entry	Amine (3)	Temperature (°C)	Yield (%) ^b	ee (%) ^[c]
1	pyrrolidine (3c)	35	30	12
2	piperidine (3d)	35	72	46
3	methyl piperidine-2-carboxylate (3e)	35	71	72
4	hexamethyleneimine (3f)	35	63	<10
5	methyl <i>L</i> -prolinate (3g)	35	85	74
6	dicyclohexylamine (3h)	35	63	<10
7	dibenzylamine (3i)	35	27	29
8	methyl <i>L</i> -prolinate (3g)	25	83	90
9	methyl <i>L</i>-prolinate (3g)	15	83	96
10	--	15	0	--
11 ^[d]	methyl <i>L</i> -prolinate (3g)	15	73	96

[a] Reaction condition: **1a** (0.2 mmol), 4CzIPN (10 mmol%), amine **3** (0.9 mmol), *tert*-butyl (*S*)-(3-methyl-1-oxobutan-2-yl)carbamate **2m** (0.9 mmol), Hantzsch ester (0.24 mmol) in 1,4-dioxane (5.0 mL), irradiated with 15 W blue LED under nitrogen atmosphere for 14 h unless otherwise noted. [b] Isolated yield. [c] The *ee* value was determined by HPLC analysis. [d] Without Hantzsch ester.


3.3 Experimental details and characterization of products 4

General procedure for the synthesis of 6-alkyl phenanthridine derivatives 4.

To a 25 mL flame-dried Schlenk tube was added **1** (0.3 mmol), 4CzIPN (0.015 mmol for achiral alkyl aldehydes or 0.03 mmol for chiral alkyl aldehydes) and Hantzsch ester (91.2 mg, 0.36 mmol). The tube was evacuated and refilled with N₂ for three times. A solution of aldehyde **2** (1.35 mmol), amine **3** (1.35 mmol) in 1,4-dioxane (7.5 mL) was added under nitrogen atmosphere. The reaction mixture was irradiated at a distance of 3 cm from 15 W blue LED and stirred at 25 °C (for **4zd-4zg**, at 15 °C) 14 h. Upon completion, the reaction mixture was concentrated under vacuum and the residue was purified by column chromatography on silica gel (200-300 mesh), eluting with the indicated

mixture of ethyl acetate (EA)/petroleum ether (PE) or DCM to give pure 6-alkyl phenanthridine **4**.


Reaction Setup:



15 W blue LED strips come with an adhesive back, so they may be easily adhered to the inside of a meshy cask. The Schlenk tube was placed in the center. Two fans were used to control the reaction temperature at room temperature. Meanwhile a thermometer was equipped to monitor the reaction temperature.


Characterization of products **4**

6-propylphenanthridine (**4a**)



4a was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as a colorless liquid (55.8 mg, 84%). ^1H NMR (500 M, CDCl_3): δ 8.67 (d, J = 8.3 Hz, 1H), 8.56 (d, J = 8.2 Hz, 1H), 8.28 (d, J = 8.2 Hz, 1H), 8.14 (dd, J = 8.2, 1.0 Hz, 1H), 7.85 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 7.72 (dddd, J = 9.2, 8.2, 7.0, 1.3 Hz, 2H), 7.64 (ddd, J = 8.2, 7.1, 1.3 Hz, 1H), 3.40-3.31 (m, 2H), 1.99 (dq, J = 15.0, 7.4 Hz, 2H), 1.15 (t, J = 7.4 Hz, 3H); ^{13}C NMR (CDCl_3 , 125 MHz): δ 162.3, 143.7, 132.9, 130.2, 129.6, 128.6, 127.2, 126.34, 126.25, 125.3, 123.6, 122.5, 121.9, 38.3, 22.9, 14.4. Its analytical data are consistent with the documented data.¹²


2-methyl-6-propylphenanthridine (**4b**)



4b was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as a colorless liquid (50.8 mg, 72%). ^1H NMR (CDCl_3 , 600 MHz): δ 8.64 (d, J = 8.3 Hz, 1H), 8.34 (s, 1H), 8.25 (d, J = 8.2 Hz, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.82 (t, J = 7.6 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 3.44-3.24 (m, 2H), 2.63 (s, 3H), 1.98 (dq, J = 14.9, 7.3 Hz, 2H), 1.15 (t, J = 7.3 Hz, 3H); ^{13}C NMR (CDCl_3 , 150 MHz): δ 161.3, 142.1, 136.0, 132.7, 130.2, 130.0,

129.3, 127.0, 126.3, 125.3, 123.5, 122.4, 121.6, 38.3, 23.0, 21.9, 14.4. HRMS (ESI) for $C_{17}H_{18}N$ $[M+H]^+$: calcd 236.1434, found 236.1486.


3-methyl-6-propylphenanthridine (4c):



4c was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as a colorless liquid (45.0 mg, 64%). 1H NMR ($CDCl_3$, 500 MHz): δ 8.56 (d, $J = 8.3$ Hz, 1H), 8.41 (d, $J = 8.4$ Hz, 1H), 8.24 (d, $J = 8.2$ Hz, 1H), 7.95 (s, 1H), 7.80 (t, $J = 7.2$ Hz, 1H), 7.65 (t, $J = 7.2$ Hz, 1H), 7.44 (dd, $J = 8.3, 1.3$ Hz, 1H), 3.36-3.33 (m, 2H), 2.59 (s, 3H), 2.01-1.94 (m, 2H),

1.15 (t, $J = 7.4$ Hz); ^{13}C NMR ($CDCl_3$, 125 MHz): δ 162.2, 143.8, 138.6, 133.0, 130.1, 129.2, 127.9, 126.7, 126.3, 125.0, 122.2, 121.7, 121.3, 38.3, 22.9, 21.5, 14.4. HRMS (ESI) for $C_{17}H_{18}N$ $[M+H]^+$: calcd 236.1434, found 236.1495.


3-chloro-6-propylphenanthridine (4d)



4d was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as a colorless liquid (48.3 mg, 63%). 1H NMR ($CDCl_3$, 600 MHz): δ 8.57 (d, $J = 8.3$ Hz, 1H), 8.45 (d, $J = 8.7$ Hz, 1H), 8.26 (d, $J = 8.2$ Hz, 1H), 8.13 (s, 1H), 7.85 (t, $J = 7.6$ Hz, 1H), 7.72 (t, $J = 7.6$ Hz, 1H), 7.57 (d, $J = 8.7$ Hz, 1H), 3.41-3.24 (m, 2H), 2.05-1.86 (m, 2H), 1.14 (t, $J = 7.3$

Hz, 3H); ^{13}C NMR ($CDCl_3$, 150 MHz): δ 163.6, 144.5, 134.1, 132.5, 130.6, 128.9, 127.5, 126.8, 126.4, 125.2, 123.3, 122.4, 122.1, 38.2, 22.6, 14.4. HRMS (ESI) for $C_{16}H_{15}ClN$ $[M+H]^+$: calcd 256.0888, found 256.0916.


8-methoxy-6-propylphenanthridine (4e)



4e was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as a white solid (53.5 mg, 71%). 1H NMR ($CDCl_3$, 600 MHz): δ 8.57 (d, $J = 9.0$ Hz, 1H), 8.47 (d, $J = 8.1$ Hz, 1H), 8.12 (d, $J = 8.1$ Hz, 1H), 7.67 (t, $J = 7.5$ Hz, 1H), 7.60 (dd, $J = 14.0, 5.0$ Hz, 2H), 7.48 (dd, $J = 8.9, 1.9$ Hz, 1H), 4.02 (s, 3H), 3.47-3.20 (m, 2H), 2.29-1.92 (m, 2H), 1.15 (t, $J = 7.3$ Hz, 3H);

^{13}C NMR ($CDCl_3$, 150 MHz): δ 161.3, 158.6, 142.9, 129.6, 127.6, 127.3, 126.6, 126.3, 124.2, 123.7, 121.4, 120.3, 107.0, 55.5, 38.4, 22.5, 14.5. Its analytical data are consistent with the documented data.¹³

6-propyl-8-(trifluoromethyl)phenanthridine (4f)




4f was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as yellow liquid (43.4 mg, 50%). 1H NMR ($CDCl_3$, 600 MHz): δ 8.75 (d, $J = 8.6$ Hz, 1H), 8.56 (d, $J = 8.1$ Hz, 1H), 8.52 (s, 1H), 8.18 (d, $J = 8.1$ Hz, 1H), 8.03 (d, $J = 8.6$ Hz, 1H), 7.80 (t, $J = 7.5$ Hz, 1H), 7.69 (t, $J = 7.5$ Hz, 1H), 3.39 (t, $J = 7.7$ Hz, 2H), 2.12-1.92 (m, 2H), 1.16 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR

($CDCl_3$, 150 MHz): δ 161.9, 144.5, 135.2, 129.9, 129.8, 129.0 (q, $J = 32.8$ Hz), 126.9, 126.1 (q, $J =$

3.0 Hz), 124.7, 124.1 (q, $J = 270.0$ Hz), 123.7 (q, $J = 4.2$ Hz), 123.6, 122.7, 122.3, 38.0, 22.6, 14.3. HRMS (ESI) for $C_{17}H_{15}F_3N$ $[M+H]^+$: calcd 290.1151, found 290.1218.


8-fluoro-6-propylphenanthridine (4g)



4g was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as colorless liquid (41.6 mg, 58%). 1H NMR ($CDCl_3$, 500 MHz): δ 8.64 (dd, $J = 9.1, 5.4$ Hz, 1H), 8.49 (d, $J = 8.0$ Hz, 1H), 8.15-8.13 (m, 1H), 7.88-7.86 (m, 1H), 7.73-7.70 (m, 1H), 7.65-7.56 (m, 3H), 3.32-3.28 (m, 2H), 2.01-1.94 (m, 2H), 1.14 (t, $J = 7.3$ Hz); ^{13}C NMR ($CDCl_3$, 125 MHz): δ 161.4

(d, $J = 246.6$ Hz), 161.3 (d, $J = 3.5$ Hz), 143.4, 129.7, 129.6, 128.5, 126.7, 126.6, 125.0 (d, $J = 8.7$ Hz), 123.2, 121.7, 119.4 (d, $J = 23.7$ Hz), 110.9 (d, $J = 21.0$ Hz), 38.3, 22.6, 14.4. HRMS (ESI) for $C_{16}H_{15}FN$ $[M+H]^+$: calcd 240.1183, found 240.1252.


6-butylphenanthridine (4h)



4h was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as colorless liquid (56.5 mg, 80%). 1H NMR ($CDCl_3$, 500 MHz): δ 8.66 (d, $J = 8.2$ Hz, 1H), 8.56 (d, $J = 8.2$ Hz, 1H), 8.28 (d, $J = 8.2$ Hz, 1H), 8.14 (d, $J = 9.0$ Hz, 1H), 7.85 (t, $J = 7.6$ Hz, 1H), 7.72 (q, $J = 8.4$ Hz, 2H), 7.63 (t, $J = 8.2$ Hz, 1H), 3.45-3.22 (m, 2H), 2.00-1.87 (m, 2H), 1.66-

1.53 (m, 2H), 1.03 (t, $J = 7.4$ Hz, 3H); ^{13}C NMR ($CDCl_3$, 125 MHz): δ 162.5, 143.8, 133.0, 130.3, 129.5, 128.6, 127.2, 126.4, 126.3, 125.3, 123.7, 122.5, 121.9, 36.2, 31.8, 23.1, 14.0. Its analytical data are consistent with the documented data.¹⁴


6-pentylphenanthridine (4i)



4i was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as colorless liquid (57.6 mg, 77%). 1H NMR ($CDCl_3$, 600 MHz): δ 8.63 (d, $J = 8.2$ Hz, 1H), 8.54 (d, $J = 8.1$ Hz, 1H), 8.26 (d, $J = 8.2$ Hz, 1H), 8.16 (d, $J = 8.1$ Hz, 1H), 7.82 (t, $J = 7.5$ Hz, 1H), 7.73 (t, $J = 7.6$ Hz, 1H), 7.69 (t, $J = 7.6$ Hz, 1H), 7.62 (t, $J = 7.5$ Hz, 1H), 3.46-3.25 (m,

2H), 1.96 (dt, $J = 15.7, 7.8$ Hz, 2H), 1.55 (dt, $J = 15.1, 7.5$ Hz, 2H), 1.49-1.39 (m, 2H), 0.96 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR ($CDCl_3$, 150 MHz): δ 162.5, 143.8, 133.0, 130.2, 129.6, 128.6, 127.2, 126.3, 126.2, 125.3, 123.7, 122.5, 121.9, 36.5, 32.2, 29.4, 22.6, 14.1. Its analytical data are consistent with the documented data.¹⁵


6-hexylphenanthridine (4j)



4j was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as colorless liquid (67.2 mg, 85%). 1H NMR ($CDCl_3$, 600 MHz): δ 8.65 (d, $J = 8.2$ Hz, 1H), 8.55 (d, $J = 8.1$ Hz, 1H), 8.27 (d, $J = 8.2$ Hz, 1H), 8.16 (d, $J = 8.1$ Hz, 1H), 7.83 (t, $J = 7.6$ Hz, 1H), 7.76-7.68 (m,


2H), 7.63 (t, $J = 7.5$ Hz, 1H), 3.39 (t, $J = 6.5$ Hz, 2H), 1.99-1.90 (m, 2H), 1.62-1.52 (m, 2H), 1.46-1.31 (m, 4H), 0.93 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR (CDCl_3 , 150 MHz): δ 162.5, 143.8, 133.0, 130.2, 129.6, 128.6, 127.2, 126.4, 126.2, 125.3, 123.7, 122.5, 121.9, 36.5, 31.8, 29.7, 29.6, 22.7, 14.1. Its analytical data are consistent with the documented data.¹⁶

6-(5-chloropentyl)phenanthridine (4k)




4k was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as Colorless liquid (67.3 mg, 79%). ^1H NMR (CDCl_3 , 600 MHz): δ 8.65 (d, $J = 8.2$ Hz, 1H), 8.55 (d, $J = 8.1$ Hz, 1H), 8.24 (d, $J = 8.2$ Hz, 1H), 8.15 (d, $J = 8.1$ Hz, 1H), 7.84 (t, $J = 7.6$ Hz, 1H), 7.76-7.67 (m, 2H), 7.64 (t, $J = 7.5$ Hz, 1H), 3.59 (t, $J = 6.7$ Hz, 2H), 3.46-3.33 (m, 2H), 2.05-1.95 (m, 2H), 1.95-1.86 (m, 2H), 1.75-1.64 (m, 2H); ^{13}C NMR (CDCl_3 , 150 MHz): δ 161.8, 143.7, 133.0, 130.3, 129.6, 128.6, 127.3, 126.4, 126.1, 125.2, 123.7, 122.5, 121.9, 45.0, 36.0, 32.6, 28.5, 27.2. HRMS (ESI) for $\text{C}_{18}\text{H}_{19}\text{ClN}$ $[\text{M}+\text{H}]^+$: calcd 284.1201, found 284.1240.

6-(3-phenylpropyl)phenanthridine (4l)




4l was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as colorless liquid (62.5 mg, 70%). ^1H NMR (CDCl_3 , 500 MHz): δ 8.65 (d, $J = 8.3$ Hz, 1H), 8.56 (d, $J = 8.0$ Hz, 1H), 8.15 (t, $J = 8.7$ Hz, 2H), 7.89-7.79 (m, 1H), 7.76-7.71 (m, 1H), 7.70-7.60 (m, 2H), 7.38-7.28 (m, 4H), 7.23 (t, $J = 7.1$ Hz, 1H), 3.49-3.35 (m, 2H), 2.89 (t, $J = 7.7$ Hz, 2H), 2.38-2.26 (m, 2H); ^{13}C NMR (CDCl_3 , 125 MHz): δ 161.8, 143.7, 142.1, 132.9, 130.3, 129.6, 128.6, 128.4, 127.2, 126.3, 126.2, 125.9, 125.2, 123.7, 122.5, 121.9, 36.0, 35.6, 30.8. Its analytical data are consistent with the documented data.¹⁷

6-(3,7-dimethyloct-6-en-1-yl)phenanthridine (4m)




4m was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as colorless liquid (53.3 mg, 56%). ^1H NMR (CDCl_3 , 500 MHz): δ 8.66 (d, $J = 8.2$ Hz, 1H), 8.56 (d, $J = 8.2$ Hz, 1H), 8.26 (d, $J = 8.1$ Hz, 1H), 8.14 (dd, $J = 8.2, 1.0$ Hz, 1H), 7.85 (ddd, $J = 8.2, 7.1, 1.2$ Hz, 1H), 7.72 (qd, $J = 6.9, 1.2$ Hz, 2H), 7.63 (ddd, $J = 8.2, 7.1, 1.3$ Hz, 1H), 5.25-5.02 (m, 1H), 3.53-3.25 (m, 2H), 2.15-1.89 (m, 3H), 1.81-1.67 (m, 5H), 1.62 (s, 3H), 1.57-1.46 (m, 1H), 1.37-1.22 (m, 1H), 1.09 (d, $J = 6.5$ Hz, 3H); ^{13}C NMR (CDCl_3 , 125 MHz): δ 162.8, 143.8, 133.0, 131.2, 130.3, 129.6, 128.6, 127.2, 126.33, 126.25, 125.2, 124.9, 123.7, 122.5, 121.9, 37.1, 36.7, 34.3, 33.1, 25.7, 25.6, 19.6, 17.7. HRMS (ESI) for $\text{C}_{23}\text{H}_{28}\text{N}$ $[\text{M}+\text{H}]^+$: calcd 318.2216, found 318.2259.

tert-butyl (1-(phenanthridin-6-yl)pentan-2-yl)carbamate (4n)




4n was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as white solid (92.8 mg, 85%). Mp: 125-127°C. ¹H NMR (500 MHz, CDCl₃): δ 8.64 (d, *J* = 8.5 Hz, 1H), 8.55 (d, *J* = 7.5 Hz, 1H), 8.40 (d, *J* = 8 Hz, 1H), 8.14-8.12 (d, 1H), 7.85-7.82 (m, 1H), 7.74-7.70 (m, 2H), 7.65-7.62 (m, 1H), 5.27 (d, *J* = 7.5 Hz, 1H), 4.25 (d, *J* = 6.5 Hz, 1H), 3.63-3.59 (m, 1H), 3.51-3.46 (m, 1H), 1.67-1.61 (m, 2H), 1.54-1.47 (s, 2H), 1.34 (m, 9H), 0.89 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 159.2, 155.7, 143.4, 132.8, 130.4, 129.7, 128.5, 127.5, 126.5, 126.3, 125.7, 123.7, 122.4, 121.9, 78.8, 50.4, 40.9, 37.0, 28.3, 19.5, 14.0. HRMS (ESI) for C₂₃H₂₉N₂O₂ [M+H]⁺: calcd 365.2224, found 365.2227.

tert-butyl (4-(methylthio)-1-(phenanthridin-6-yl)butan-2-yl)carbamate (4o)




4o was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as white solid (73.7 mg, 62%). Mp: 117-119 °C. ¹H NMR (500 MHz, CDCl₃): δ 8.65 (d, *J* = 8 Hz, 1H), 8.56 (d, *J* = 8 Hz, 1H), 8.37 (d, *J* = 7.5 Hz, 1H), 8.12 (d, *J* = 7.5 Hz, 1H), 7.86 (t, *J* = 7 Hz, 1H), 7.75-7.71 (m, 2H), 7.66-7.63 (m, 1H), 5.46 (d, *J* = 7 Hz, 1H), 4.42-4.35 (m, 1H), 3.66-3.53 (m, 2H), 2.70-2.55 (m, 2H), 2.06 (s, 3H), 2.02-1.97 (m, 2), 1.35 (s, 9H); ¹³C NMR (125 MHz, CDCl₃): δ 158.7, 155.6, 143.3, 132.9, 130.6, 129.7, 128.6, 127.62, 127.61, 126.6, 126.2, 125.7, 123.7, 122.5, 122.0, 79.1, 49.8, 40.2, 34.2, 31.0, 28.3, 15.5. HRMS (ESI) for C₂₃H₂₉N₂O₂S [M+H]⁺: calcd 397.1944, found 397.1946.

6-(cyclohexylmethyl)phenanthridine (4p)



4p was isolated via column chromatography (eluent: PE/EA = 100/1 to PE/EA = 20/1) as colorless liquid (56.2 mg, 68%). ¹H NMR (CDCl₃, 600 MHz): δ 8.67 (d, *J* = 8.3 Hz, 1H), 8.57 (d, *J* = 8.1 Hz, 1H), 8.29 (d, *J* = 8.2 Hz, 1H), 8.17 (d, *J* = 8.1 Hz, 1H), 7.85 (t, *J* = 7.6 Hz, 1H), 7.77-7.69 (m, 2H), 7.64 (t, *J* = 7.5 Hz, 1H), 3.29 (d, *J* = 7.2 Hz, 2H), 2.04 (s, 1H), 1.72 (m, 5H), 1.22 (s, 5H); ¹³C NMR (CDCl₃, 150 MHz): δ 161.5, 143.7, 132.9, 130.2, 129.6, 128.6, 127.1, 126.7, 126.3, 125.8, 123.6, 122.4, 121.9, 43.7, 38.8, 33.7, 26.5, 26.3. Its analytical data are consistent with the documented data.¹⁸


tert-butyl 2-(phenanthridin-6-ylmethyl)morpholine-4-carboxylate (4q)



4q was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (61.2 mg, 54%). ¹H NMR (500 MHz, CDCl₃): δ 8.66 (d, *J* = 8.0 Hz, 1H), 8.57 (d, *J* = 8.0 Hz, 1H), 8.30 (d, *J* = 8.0 Hz, 1H), 8.16 (d, *J* = 8.5 Hz, 1H), 7.8-7.84 (m, 1H), 7.75-7.71 (m, 2H), 7.67-7.64 (m, 1H), 4.23-4.17 (m, 2H), 3.87 (d, *J* = 10.0 Hz, 2H), 3.71-3.67 (m, 1H), 3.55-3.42 (m, 2H),


3.03-2.87 (m, 2H), 1.44 (s, 9H); ^{13}C NMR (125 MHz, CDCl_3): δ 154.7, 143.6, 132.9, 131.4, 130.4, 129.8, 128.6, 127.3, 126.6, 126.4, 125.8, 123.7, 122.4, 121.9, 79.9, 75.2, 66.7, 28.4. HRMS (ESI) for $\text{C}_{23}\text{H}_{27}\text{N}_2\text{O}_3$ $[\text{M}+\text{H}]^+$: calcd 379.2016, found 379.2020.

***tert*-butyl (*S*)-2-(phenanthridin-6-ylmethyl)pyrrolidine-1-carboxylate (**4r**)**




4r was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (85.4 mg, 79%). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak IG-3 column, *ee* = 97% (HPLC: 254 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, t_r (major) = 10.69 min, t_r (minor) = 8.97 min). $[\alpha]_D^{25} = +77.1$ (c 1.0, CH_2Cl_2). ^1H NMR (500 MHz, CDCl_3): δ {8.80 (d, $J = 7.8$ Hz) + 8.50 (d, $J = 7.8$ Hz)}, 8.67-8.62 (m, 1H), 8.56 (d, $J = 8.0$ Hz, 1H), 8.14 (d, $J = 8.0$ Hz, 1H), 7.85-7.63 (m, 4H), 4.49-4.45 (m, 1H), {4.19 (d, $J = 11.0$ Hz, 0.5H) + 3.99 (dd, $J = 12.8$ Hz, $J_2 = 3.6$ Hz, 0.5 H)}, 3.51-3.32 (m, 2H), 3.18-3.09 (m, 1H), 2.09-1.67 (m, 4H), {1.54 (s, 4.5H) + 1.50 (s, 4.5 H)}; ^{13}C NMR (125 MHz, CDCl_3) δ 159.9 & 159.4 (due to rotamer), 154.8 & 154.5 (due to rotamer), 143.8 & 143.7 (due to rotamer), 132.9 & 132.7 (due to rotamer), 130.4, 129.8 & 129.7 (due to rotamer), 128.6 & 128.4 (due to rotamer), 127.84 & 127.82 (due to rotamer), 127.5 & 127.4 (due to rotamer), 127.2 & 127.1 (due to rotamer), 126.7 & 126.6 (due to rotamer), 126.6 & 126.5 (due to rotamer), 125.8 & 125.6 (due to rotamer), 122.4 & 122.0 (due to rotamer), 121.9, 79.8 & 79.1 (due to rotamer), 57.1 & 56.9 (due to rotamer), 46.9 & 46.5 (due to rotamer), 41.2 & 40.4 (due to rotamer), 30.0 & 28.9 (due to rotamer), 28.7, 23.5 & 22.7 (due to rotamer). HRMS (ESI) for $\text{C}_{23}\text{H}_{26}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: calcd 363.2067, found 363.2069. Its analytical data are consistent with the documented data.¹⁹

Chiral HPLC Charts for **4r**:



Signal: DAD1A, Sig=254.4 Ref=off						
RT [min]	Type	Width [min]	Area	Height	Area%	Name
8.972	BB	1.39	6530.703	420.19	49.5273	
10.709	VBA	1.60	6655.374	364.26	50.4727	

Figure S1. The HPLC chart of rac-**4r**




Signal: DAD1A,Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%	Name
8.968	BB	1.18	623.450	40.57	1.4824	
10.691	VB	1.62	41432.673	2161.85	98.5176	

Figure S2. The HPLC chart of **4r**

Note: at RT, this compound appears as a mixture of rotamers. This phenomenon was widely observed in the *N*-Boc pyrrolidine derivatives.^{19,20} And this phenomenon was disappeared when the protecting group (Boc) was removed. The NMR spectra of *de*-Boc-**4r** was listed as blow.


(S)-6-(pyrrolidin-2-ylmethyl)phenanthridine (*de*-Boc-4r**)**



¹H NMR (500 MHz, CDCl₃): δ 8.36 (d, *J* = 8.4 Hz, 1H), 8.24 (d, *J* = 8.4 Hz, 1H), 8.04 (d, *J* = 6.8 Hz, 1H), 7.93 (d, *J* = 8.0 Hz, 1H), 7.68 (t, *J* = 7.60 Hz, 1H), 7.59-7.50 (m, 2H), 7.46-7.42 (m, 1H), 4.31-4.23 (m, 1H), 3.81-3.75 (m, 1H), 3.57-3.51 (m, 1H), 3.34-3.29 (m, 2H), 2.21-2.17 (m, 1H), 2.05-1.86 (m, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 156.8, 145.6, 132.4, 130.7, 129.6, 128.6, 127.5, 126.8, 125.2, 124.7, 123.4, 122.2, 121.6, 58.2,

44.9, 35.1, 30.1, 23.4.

tert-butyl (S)-2-((2-methylphenanthridin-6-yl)methyl)pyrrolidine-1-carboxylate (4s**)**




4s was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (78.9 mg, 70%). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak IG-3 column, *ee* > 99% (HPLC: 210 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, *t_r* (major) = 11.90 min, *t_r* (minor) = 9.09 min). [α]_D²⁵ = +48.2 (c 1.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃): δ {8.78 (d, *J* = 7.9

Hz, 0.5H) + 8.49 (d, *J* = 8.1 Hz, 0.5H)}, 8.63 (dd, *J*₁ = 14.9 Hz, *J*₂ = 8.2 Hz, 1H), 8.34 (s, 1H), 8.03 (d, *J* = 8.1 Hz, 1H), 7.85-7.81 (m, 1H), 7.79-7.65 (m, 1H), 7.57-7.53 (m, 1H), 4.47-4.43 (m, 1H), {4.18 (dd, *J*₁ = 12.7 Hz, *J*₂ = 2.3 Hz, 0.5H) + 3.98 (dd, *J* = 12.9, 4.1 Hz, 0.5 H)}, 3.52-3.48 (m, 1H), 3.43-3.29 (m, 1H), 3.14-3.05 (m, 1H), 2.63 (s, 3H), 2.11-2.01 (m, 2H), 1.87-1.69 (m, 2H), {1.54 (s, 4H) + 1.52 (s, 5H)}; ¹³C NMR (125 MHz, CDCl₃): δ 158.9 & 158.4, 154.8 & 154.5, 142.1 & 142.0, 136.4

&136.1, 132.6 & 132.5, 130.3 &130.1, 130.2, 129.5 &129.4, 127.7 & 127.4, 126.9 & 126.6, 125.8 & 125.7, 123.6 & 123.5, 122.4 & 122.0, 121.5, 79.7 & 79.0, 57.1 & 56.9, 46.8 & 46.5, 41.1 &40.4, 29.9 & 28.8, 28.7, 23.5 & 22.6, 21.9. HRMS (ESI) for C₂₄H₂₉N₂O₂ [M+H]⁺: calcd 377.2224, found 377.2222.


Chiral HPLC Charts for **4s**:



Signal: DAD1A, Sig=210,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%	Name
9.085	BBA	1.05	13933.145	659.80	49.0144	
11.851	BBA	1.53	14493.515	656.14	50.9856	

Figure S3. The HPLC chart of rac-**4s**




Signal: DAD1A, Sig=210,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%	Name
11.898	BBA	1.42	4319.406	202.61	100.0000	

Figure S4. The HPLC chart of **4s**


tert-butyl (S)-2-((2-bromophenanthridin-6-yl)methyl)pyrrolidine-1-carboxylate (4t)



4t was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (101.7 mg, 77%). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak IG-3 column, *ee* = 94% (HPLC: 254 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, *t_r* (major) = 12.58 min, *t_r* (min) = 10.16 min). [α]_D²⁵ = +92.4 (c 1.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃): δ {8.78 (d, *J* =

7.7 Hz, 0.5H)+ 8.48 (d, $J = 8.1$ Hz, 0.5H)}, 8.66 (s, 1H), 8.54 (dd, $J_1 = 14.6$, $J_2 = 8.1$ Hz, 1H), 7.99-7.97 (m, 1H), 7.88-7.70 (m, 3H), 4.46-4.43 (m, 1H), 4.15 (dd, $J_1 = 12.8$ Hz, $J_2 = 2.8$ Hz, 1H) + 3.94 (dd, $J_1 = 13.0$ Hz, $J_2 = 4.3$ Hz, 0.5H)}, 3.54-3.31 (m, 2H), 3.15-3.05 (m, 1H), 2.08-1.99 (m, 2H), 1.89-1.70 (m, 2H), {1.53 (s, 4.5H) + 1.48 (s, 4.5H)}; ^{13}C NMR (125 MHz, CDCl_3): δ 160.4 & 159.9, 154.8 & 154.5, 142.44 & 142.36, 131.9 & 131.7, 131.6, 131.44 & 131.35, 130.7, 128.5 & 127.8, 127.5 & 126.6, 125.9 & 125.7, 125.4 & 125.2, 124.8, 122.4 & 122.0, 120.5 & 120.3, 79.8 & 79.1, 57.0 & 56.8, 46.8 & 46.5, 41.1 & 40.4, 30.0 & 29.0, 28.6, 23.5 & 22.6. HRMS (ESI) for $\text{C}_{23}\text{H}_{26}\text{BrN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: calcd 441.1172, found 441.1175.


Chiral HPLC Charts for **4t**:



Signal: DAD1A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%	Name
10.274	BV	1.35	17690.281	880.02	49.3363	
12.677	VBA	1.94	18166.265	790.46	50.6637	

Figure S5. The HPLC chart of rac-**4t**




Signal: DAD1A, Sig=254,4 Ref=off

RT [min]	Type	Width [min]	Area	Height	Area%	Name
10.158	BB	2.11	848.252	42.36	3.0003	
12.583	BBA	2.15	27423.671	1184.87	96.9997	

Figure S6. The HPLC chart of **4t**


methyl (S)-6-((1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methyl)phenanthridine-2-carboxylate (4u)



4u was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (85.7 mg, 68%). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak AD-H column, *ee* = 96% (HPLC: 254 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, *t_r* (major) = 19.19 min, *t_r* (min) = 20.56 min). $[\alpha]_D^{25} = +115$ (c 1.0, CH₂Cl₂).

¹H NMR (500 MHz, CDCl₃): δ 9.29 (s, 1H), {8.80 (d, *J* = 8.0 Hz, 0.5H) + 8.49 (d, *J* = 8.0 Hz, 0.5H)}, 8.73 (dd, *J*₁ = 15.1 Hz, *J*₂ = 8.2 Hz, 2H), 8.33 (t, *J* = 8.4 Hz, 1H), 8.15 (dd, *J*₁ = 8.2 Hz, *J*₂ = 3.9 Hz, 1H), 7.90 (dd, *J*₁ = 12.8 Hz, *J*₂ = 6.8 Hz, 1H), 7.84-7.71 (m, 1H), 4.49 (dd, *J*₁ = 14.3 Hz, *J*₂ = 7.1 Hz, 3H), {4.19 (dd, *J*₁ = 12.7 Hz, *J*₂ = 2.7 Hz, 0.5H) + 3.97 (dd, *J*₁ = 13.0 Hz, *J*₂ = 4.3 Hz, 0.5H)}, 3.54-3.31 (m, 2H), 3.19-3.09 (m, 1H), 2.16-2.07 (m, 3H), 1.90-1.72 (m, 2H), 1.49 (dd, *J*₁ = 24.5 Hz, *J*₂ = 10 Hz, 9H); ¹³C NMR (125 MHz, CDCl₃): δ 166.52 & 166.49, 162.4 & 161.9, 154.7 & 154.4, 146.10 & 146.05, 132.9 & 132.7, 130.9, 129.8 & 129.7, 128.6 & 128.3, 128.0 & 127.9, 127.7 & 127.5, 126.7, 125.9 & 125.7, 124.6, 123.3 & 123.1, 122.6 & 122.2, 79.7 & 79.1, 61.3 & 61.2, 57.0 & 56.8, 46.8 & 46.4, 41.3 & 40.6, 30.1 & 28.9, 28.6, 23.5 & 22.6. HRMS (ESI) for C₂₅H₂₉N₂O₄ [M+H]⁺: calcd 421.2122, found 421.2126.


Chiral HPLC Charts for **4u**:



Signal: DAD1 254.0;4 Ref off

RT [min]	Type	Width [min]	Area	Height	Area%	Name
19.452	BV	1.77	19091.931	503.26	49.9854	
20.808	VB	3.17	19103.059	427.76	50.0146	

Figure S7. The HPLC chart of rac-**4u**




Signal: DAD1 254.0;4 Ref off

RT [min]	Type	Width [min]	Area	Height	Area%	Name
19.190	BV	2.21	5288.271	139.08	97.8654	
20.559	VB	1.71	115.345	2.70	2.1346	

Figure S8. The HPLC chart of **4u**


tert-butyl (S)-2-((2-cyanophenanthridin-6-yl)methyl)pyrrolidine-1-carboxylate (4v**)**



4v was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (89.4 mg, 77%). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak AD-H column, *ee* = 97% (HPLC: 254 nm, *n*-Hexane/isopropanol = 80/20, flow rate 0.6 mL/min, 30 °C, *t_r* (major) = 8.56 min, *t_r* (min) = 8.97 min). $[\alpha]_D^{25} = +16.0$ (c 1.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃): δ

8.87 (s, 1H), {8.81 (d, *J* = 7.9 Hz, 0.5H) + 8.51 (d, *J* = 8.0 Hz, 0.5H)}, 8.59 (dd, *J*₁ = 18.3 Hz, *J*₂ = 8.0 Hz, 2H), 8.19-8.16 (m, 1H), 7.96-7.75 (m, 3H), 4.46 (s, 1H), {4.17 (dd, *J*₁ = 12.8 Hz, *J*₂ = 2.9 Hz, 0.5H) + 3.96 (dd, *J*₁ = 13.0 Hz, *J*₂ = 4.1 Hz, 0.5H)} 3.51-3.32 (m, 2H), 3.21-3.10 (m, 1H), 2.07-1.98 (m, 2H), 1.86-1.74 (m, 2H), {1.51 (s, 5H) + 1.45 (s, 4H)}; ¹³C NMR (125 MHz, CDCl₃): δ 163.5 & 163.0, 154.8 & 154.4, 145.44 & 145.38, 131.7 & 131.53, 131.47, 131.0 & 130.9, 130.2 & 130.0, 129.1 & 128.5, 127.7, 126.9, 126.1 & 126.0, 124.02 & 123.9, 122.4 & 122.0, 109.9 & 109.6, 79.8 & 79.2, 57.0 & 56.8, 53.4, 46.8 & 46.4, 41.3 & 40.6, 30.2 & 29.1, 28.6, 23.5 & 22.6. HRMS (ESI) for C₂₄H₂₆N₃O₂ [M+H]⁺: calcd 388.2020, found 388.2022.


Chiral HPLC Charts for **4v**:



Signal: DAD1 254.0;4 Ref off

RT [min]	Type	Width [min]	Area	Height	Area%	Name
8.564	BV	0.62	2130.112	179.42	49.6671	
9.013	VB	0.91	2158.664	175.15	50.3329	

Figure S9. The HPLC chart of rac-4v




Signal: DAD1 254.0;4 Ref off

RT [min]	Type	Width [min]	Area	Height	Area%	Name
8.559	BV	0.74	17968.373	1491.63	98.5123	
8.974	VB	0.90	271.354	27.88	1.4877	

Figure S10. The HPLC chart of 4v

tert-butyl (S)-2-((3-(trifluoromethyl)phenanthridin-6-yl)methyl)pyrrolidine-1-carboxylate (4w)




4w was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (100.6 mg, 78%). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak IG-3 column, *ee* > 99% (HPLC: 210 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, *t_r* (major) = 7.95 min, *t_r* (minor) = 6.80 min). $[\alpha]_D^{25} = +24.4$ (c 1.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃): δ

{8.85 (s, 1.5H), 8.52 (d, *J* = 8.0 Hz, 0.5H)}, 8.65 (dd, *J*₁ = 14.9 Hz, *J*₂ = 8.2 Hz, 1H), 8.23-8.21 (m, 1H), 7.93-7.89 (m, 2H), {7.85 (t, *J* = 7.3 Hz, 0.5H) + 7.75 (t, *J* = 7.3 Hz, 0.5H)}, 4.47 (s, 1H), {4.19 (dd, *J*₁ = 12.6 Hz, *J*₂ = 2.1 Hz, 0.5H) + 3.94 (dd, *J*₁ = 12.9 Hz, *J*₂ = 3.7 Hz, 0.5H)}, 3.52-3.49 (m, 1H), 3.47-3.32 (m, 1H), 3.21-3.11 (m, 1H), 2.08-2.01 (m, 3H), 1.89-1.73 (m, 2H), {1.53 (s, 5H) + 1.48 (s,

4H)}; ^{13}C NMR (125 MHz, CDCl_3): δ 162.4 & 161.9, 154.7 & 154.4, 145.1, 132.4 & 132.3, 131.0 & 130.6, 130.5, 128.6, 128.0, 127.6, 126.8, 126.0 & 125.9, 125.5, 124.5 & 124.3, 124.4 (q, $J = 260$ Hz) 123.4 & 123.3, 122.4 & 122.0, 119.8 (q, $J = 3.75$ Hz), 79.8 & 79.1, 57.0 & 56.8, 46.9 & 46.4, 41.1 & 40.5, 30.0 & 29.0, 28.6, 23.5 & 22.6. HRMS (ESI) for $\text{C}_{24}\text{H}_{26}\text{F}_3\text{N}_3\text{O}_2$ $[\text{M}+\text{H}]^+$: calcd 431.1941, found 431.1944.


Chiral HPLC Charts for **4w**:



Signal: VWD1A,Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
6.788	BB	1.13	12005.586	948.29	48.6766	
7.936	BBA	1.05	12658.416	890.01	51.3234	

Figure S11. The HPLC chart of rac-**4w**




Signal: VWD1A,Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
6.804	BB	0.50	35.547	3.02	0.3255	
7.949	BBA	1.04	10884.872	763.55	99.6745	

Figure S12. The HPLC chart of **4w**


tert-butyl (S)-2-((8-methoxyphenanthridin-6-yl)methyl)pyrrolidine-1-carboxylate (4x)



4x was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (83.6 mg, 71%). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak IG-3 column, *ee* > 99% (HPLC: 210 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, *t_r* (major) = 7.00 min, *t_r* (min) = 6.40 min). $[\alpha]_D^{25} = +65.9$ (c 1.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃): δ 8.52-8.45 (m, 3H), 8.11

(d, *J* = 8.0 Hz, 1H), 7.66-7.58 (m, 2H), 7.47-7.45 (m, 1H), 4.41-4.21 (m, 1H), {4.16 (s, 2.5 H) + 4.00 (s, 0.5H)}, 3.53-3.51 (m, 1H), 3.34-3.31 (m, 1H), 2.99-2.94 (m, 1H), 2.24-2.13 (m, 2H), 1.90-1.85 (m, 1H), 1.74-1.67 (m, 1H), {1.53 (s, 7H) + 1.30 (s, 2H)}; ¹³C NMR (125 MHz, CDCl₃): δ 159.3 & 159.2, 154.7, 142.9, 129.6, 127.3, 127.2, 127.0, 126.4, 124.1, 123.5, 121.9, 121.4, 107.4, 79.1, 57.1 & 56.2, 46.8, 41.3, 28.9, 28.6, 26.9, 23.6. HRMS (ESI) for C₂₄H₂₉N₃O₂ [M+H]⁺: calcd 393.2173, found 393.2175.


Chiral HPLC Charts for **4x**:



Signal: VWD1A, Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
6.373	BV	0.58	7666.956	632.52	50.8003	
6.967	VB	0.76	7425.387	560.63	49.1997	

Figure S13. The HPLC chart of rac-**4x**




Signal: VWD1A,Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
6.403	BB	0.37	13.371	1.41	0.3848	
6.997	BB	1.23	3461.589	269.89	99.6152	

Figure S14. The HPLC chart of **4x**


tert-butyl (S)-2-((8-methylphenanthridin-6-yl)methyl)pyrrolidine-1-carboxylate (4y**)**



4y was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (83.4 mg, 74%). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak IG-3 column, *ee* = 97 % (HPLC: 210 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, *t_r* (major) = 8.42 min, *t_r* (min) = 7.22 min). $[\alpha]_D^{25} = +59.3$ (c 1.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃): δ 8.80 (d, *J* = 8.1 Hz, 1H),

8.74-8.43 (m, 1H), 8.18 (d, *J* = 7.9 Hz, 1H), 7.75-7.57(m, 4H), 4.47-4.46 (m, 1H), 4.22-4.00 (m, 1H), 3.55-3.34 (m, 3H), 3.14 (s, 1H), 3.13-3.07 (m, 1H), 2.12-1.98 (m, 2H), 1.87-1.67 (m, 2H), 1.54 (s, 9H); ¹³C NMR (125 MHz, CDCl₃): δ 160.2 & 159.7, 154.8 & 154.5, 144.94 & 144.87, 135.6, 135.2, 134.7 & 134.6, 132.4, 130.1 & 129.9, 127.8, 127.6, 127.3 & 127.1, 126.5, 125.9 & 125.7, 125.5 & 125.1, 79.7 & 79.1, 57.1 & 56.9, 46.8 & 46.5, 41.6 & 40.9, 29.9 & 28.9, 28.7, 26.9, 23.5 & 22.6. HRMS (ESI) for C₂₄H₂₉N₃O₂ [M+H]⁺: calcd 377.2224, found 377.2226.


Chiral HPLC Charts for **4y**:



Signal: VWD1A,Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
7.320	BB	0.64	17427.808	1385.36	49.0777	
8.370	BB	0.78	18082.862	1215.56	50.9223	

Figure S15. The HPLC chart of rac-4y




Signal: VWD1A,Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
7.224	BBA	0.83	33.387	1.91	1.2909	
8.417	BBA	0.99	2552.880	165.35	98.7091	

Figure S16. The HPLC chart of 4y


***tert*-butyl (*S*)-2-((8-(trifluoromethyl)phenanthridin-6-yl)methyl)pyrrolidine-1-carboxylate (4z)**



4z was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (69.4 mg, 54%). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak IG-3 column, *ee* > 99 % (HPLC: 210 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, *t_r* (major) = 6.845 min, *t_r* (minor) = 6.064 min). $[\alpha]_D^{25} = +18.9$ (c 1.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃): δ {9.16 (s, 0.6H) + 8.53-8.52 (m, 1.4 H)}, 8.73-8.68 (m, 1H), 8.15 (d, *J* = 8.0 Hz, 1H), 8.03-7.99 (m, 1H), 7.78-7.75 (m, 1H), 7.67 (m, 1H), 4.51 (d, *J* = 39.1 Hz, 1H), {4.17-4.06 (m, 0.6H) + 3.97-3.94 (m, 0.4H)}, 3.52-3.34 (m, 2H), 3.29-3.12 (m, 1H), 2.05-1.86 (m, 4H), {1.48 (s, 5H), 1.28(s, 4H)}; ¹³C NMR (125 MHz, CDCl₃): δ 159.8 & 159.2, 154.8 & 154.4, 144.4, 135.0 & 134.9, 130.0, 129.8, 129.5, 127.09, 126.8,

126.2 & 126.2, 125.2 & 125.0, 123.7 & 123.5, 123.1, 122.8 & 122.6, 122.3, 79.4 & 79.2, 57.1 & 56.7, 46.7 & 46.3, 40.8 & 40.6, 31.0 & 29.6, 28.5 & 28.3, 22.9 & 22.6. HRMS (ESI) for C₂₄H₂₉N₂O₃ [M+H]⁺: calcd 431.1941, found 431.1944.


Chiral HPLC Charts for **4z**:



Signal: VWD1A, Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
6.064	BB	0.63	24200.173	1998.47	48.9653	
6.811	BBA	0.82	25222.906	2011.21	51.0347	

Figure S17. The HPLC chart of rac-**4z**




Signal: VWD1A, Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
6.845	BBA	0.93	1298.133	105.15	100.0000	

Figure S18. The HPLC chart of rac-**4z**


tert-butyl (S)-2-((8-(trifluoromethoxy)phenanthridin-6-yl)methyl)pyrrolidine-1-carboxylate (4za)



4za was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (95.0 mg, 71%). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak IG-3 column, *ee* > 99% (HPLC: 210 nm, *n*-Hexane/isopropanol = 95/5, flow rate 0.4 mL/min, 30 °C, *t_r* (major) = 12.32 min, *t_r* (minor) = 9.19 min). $[\alpha]_D^{25} = +70.3$ (c 1.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃): δ {8.71-8.65 (m,

1.45H) + 8.22 (s, 0.5H)}, 8.54-8.52 (m, 1H), 8.16-8.14 (m, 1H), 7.78-7.64 (m, 3H), 4.45 (s, 1H), {4.06 (dd, $J_1 = 12.7$ Hz, $J_2 = 2.1$ Hz, 0.5H), 3.94 (dd, $J_1 = 13.2$ Hz, $J_2 = 4.7$ Hz, 0.5H)}, 3.54-3.51 (m, 1H), 3.48-3.31 (m, 1H), 3.19-3.12 (m, 1H), 2.09-1.83 (m, 4H), {1.49 (s, 4H), 1.44 (s, 5H)}; ^{13}C NMR (125 MHz, CDCl_3): δ 159.24 & 159.21, 158.61 & 158.58, 154.7 & 154.5, 148.1 & 147.9, 143.8, 131.5 & 131.3, 130.02 & 130.01, 129.1 & 128.9, 127.1 & 126.8, 124.7 & 124.3, 123.8, 123.0 & 122.8, 121.9, 120.6 (q, $J = 264.2$ Hz), 118.8 & 118.2, 79.8 & 79.2, 57.0 & 56.6, 46.7 & 46.5, 41.0 & 40.5, 30.3 & 29.4, 28.5, 23.7 & 22.7. HRMS (ESI) for $\text{C}_{24}\text{H}_{26}\text{F}_3\text{N}_3\text{O}_3$ $[\text{M}+\text{H}]^+$: calcd 447.1890, found 447.1893.


Chiral HPLC Charts for **4za**:



Signal: VWD1A,Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
9.176	VBA	1.22	1023.107	65.10	49.3407	
12.317	BB	0.97	1050.451	52.20	50.6593	

Figure S19. The HPLC chart of rac-**4za**




Signal: VWD1A,Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
9.188	BB	0.48	3.472	0.27	0.3561	
12.323	BV	1.38	971.679	49.89	99.6439	


Figure S20. The HPLC chart of **4za**

tert-butyl (*S*)-2-((7,9-dimethylphenanthridin-6-yl)methyl)pyrrolidine-1-carboxylate (**4zb**)



4zb was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (78.5 mg, 67%). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak IG-3 column, *ee* = 97% (HPLC: 210 nm, n-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, *t_r* (major) = 9.40 min, *t_r* (min) = 8.57 min). $[\alpha]_D^{25} = +85.5$ (c 1.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃): δ 8.50 (d, *J* = 7.8 Hz, 1H), 8.33 (d, *J* = 8.3 Hz, 1H), 8.03 (d, *J* = 8.0 Hz, 1H), 7.66-7.57 (m, 2H), 7.32 (s, 1H), 4.67 (d, *J* = 1.9 Hz, 1H), {4.22 (d, *J* = 13.9 Hz, 0.5H), 4.05 (d, *J* = 14.6 Hz, 0.5H)}, 3.51-3.34 (m, 3H) 3.01 (d, *J* = 35.2 Hz, 3H), 2.57(s, 3H), 2.12-1.68 (m, 4H), {1.47 (s, 4H), 1.32 (s, 5H)}; ¹³C NMR (125 MHz, CDCl₃) δ 159.1, 154.7, 143.0, 139.5, 134.6, 133.5, 129.4, 128.2, 126.1, 124.4, 123.4, 122.1, 120.6, 120.4, 79.1 & 78.9, 56.9, 46.8 & 46.4, 44.9 & 44.3, 31.8 & 30.2, 28.5, 26.3 & 26.0, 23.5 & 22.9, 21.7. HRMS (ESI) for C₂₅H₃₁N₂O₃ [M+H]⁺: calcd 391.2380, found 391.2184.


Chiral HPLC Charts for **4zb**:



Signal: VWD1A, Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
8.525	BV	0.79	25933.706	1869.41	49.0157	
9.284	VBA	0.79	26975.270	1699.03	50.9843	

Figure S21. The HPLC chart of rac-**4zb**




Signal: VWD1A, Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
8.570	BB	1.06	32.969	1.99	1.3911	
9.404	BBA	0.76	2336.972	192.91	98.6089	

Figure S22. The HPLC chart of **4zb**


***tert*-butyl (*S*)-2-((10-methoxyphenanthridin-6-yl)methyl)pyrrolidine-1-carboxylate (**4zc**)**



4zc was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (61.1 mg, 53%). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak IG-3 column, *ee* > 99% (HPLC: 210 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, *t_r* (major) = 10.73 min, *t_r* (min) = 11.70 min). $[\alpha]_D^{25} = +112.0$ (c 1.0, CH₂Cl₂).

¹H NMR (500 MHz, CDCl₃): δ 9.49 (dd, *J*₁ = 8.5 Hz, *J*₂ = 1.1 Hz, 1H), 8.46-8.14 (m, 2H), 7.77-7.60 (m, 3H), 7.34 (d, *J* = 7.9 Hz, 1H), 4.49-4.46 (m, 1H), 4.20-3.98 (m, 2H), 4.16 (s, 3H), 3.55-3.31 (m, 2H), 3.15-3.06 (m, 1H), 2.14-2.02 (m, 2H), 2.01-1.78 (m, 2H), 1.54 (s, 9H); **¹³C NMR** (125 MHz, CDCl₃): δ 158.9 & 158.5, 154.8 & 154.5, 144.3, 129.5 & 129.4, 127.9, 127.7, 127.3, 126.4, 126.2, 123.6 & 123.5, 123.4 & 123.2, 119.7, 118.9, 111.6 & 111.5, 79.7 & 79.0, 57.0 & 56.8, 55.8, 46.8 & 46.5, 41.6 & 40.9, 29.9 & 28.9, 28.7, 23.5 & 22.7. HRMS (ESI) for C₂₄H₂₉N₂O₃ [M+H]⁺: calcd 393.2173, found 393.2175.


Chiral HPLC Charts for **4zc**:



Signal: VWD1A,Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
10.697	VV	1.08	24083.689	1265.03	50.3764	
11.668	VBA	1.91	23723.777	1034.18	49.6236	

Figure S23. The HPLC chart of rac-4zc




Signal: VWD1A,Wavelength=210 nm

RT [min]	Type	Width [min]	Area	Height	Area%	Name
10.725	BV	1.30	14661.401	773.84	99.2836	
11.700	VB	1.48	105.790	3.47	0.7164	

Figure S24. The HPLC chart of 4zc

***tert*-butyl (*R*)-(3-methyl-1-(phenanthridin-6-yl)butan-2-yl)carbamate (4zd):**



4zd was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (86.25 mg, 83%, 96% *ee*). Mp: 144-146 °C Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak AD column, *ee* = 96 % (HPLC: 210 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, t_r (major) = 10.856 min, t_r (min) = 7.494 min). $[\alpha]_D^{25} =$

+8.2 (c 1.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃) δ 8.66 (d, *J* = 8.2 Hz, 1H), 8.56 (dd, *J*₁ = 8.1 Hz, *J*₂ = 1.1 Hz, 1H), 8.32 (d, *J* = 8.0 Hz, 1H), 8.13 (dd, *J*₁ = 8.1, *J*₂ = 0.7 Hz, 1H), 7.90-7.82 (m, 1H), 7.75-7.71 (m, 2H), 7.66-7.62 (m, 1H), 5.24 (d, *J* = 8.3 Hz, 1H), 4.12-4.07 (m, 1H), 3.65 (dd, *J*₁ = 14.2, *J*₂ = 4.6 Hz, 1H), 3.40 (dd, *J* = 14.1, 8.5 Hz, 1H), 2.09-2.03 (m, 1H), 1.20 (s, 9H), 1.10 (d, *J* = 6.8 Hz, 3H), 1.01 (d, *J* = 6.7 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 159.4, 155.8, 143.4, 132.9, 130.5, 129.6,

128.5, 127.5, 126.5, 126.1, 125.6, 123.8, 122.5, 121.9, 78.7, 55.6, 38.1, 31.7, 28.1, 19.4, 18.1. HRMS (ESI) for C₂₃H₂₉N₂O₂ [M+H]⁺: calcd 365.2224, found 365.2226.

Chiral HPLC Charts for **4zd**:




Figure S25. The HPLC chart of rac-**4zd**





Figure S26. The HPLC chart of **4zd**

tert-butyl (S)-(1-(phenanthridin-6-yl)propan-2-yl)carbamate (4ze)



4ze was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as white solid (89.6 mg, 89%, 93% *ee*). Mp: 155-157 °C. Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak ID column, *ee* = 93 % (HPLC: 210 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, *t_r* (major) = 14.398 min, *t_r* (minor) = 12.758 min).

[α]_D²⁵ = +22.4 (c 1.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃): δ 8.65 (d, *J* = 8.5 Hz, 1H), 8.56 (d, *J* = 8.0 Hz, 1H), 8.42 (d, *J* = 5.5 Hz, 1H), 8.14 (dd, *J*₁ = 8.1 Hz, *J*₂ = 0.9 Hz, 1H), 7.87-7.84 (m, 1H), 7.75-7.71 (m, 2H), 7.66-7.63 (m, 1H), 5.29 (d, *J* = 13.6 Hz, 1H), 4.34 (d, *J* = 6.0 Hz, 1H), 3.74-3.69 (m, 1H), 3.40 (dd, *J*₁ = 13.9 Hz, *J*₂ = 7.0 Hz, 1H), 1.37 (s, 9H), 1.29 (d, *J* = 6.6 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): δ 159.1, 155.4, 143.4, 132.9, 130.5, 129.7, 128.6, 127.6, 126.6, 126.4, 125.7, 123.7,

122.4, 121.9, 79.0, 46.5, 42.4, 28.3, 20.7. HRMS (ESI) for C₂₃H₂₈N [M+H]⁺: calcd 337.1911, found 337.1907.

Chiral HPLC Charts for **4ze**:

VWD1 A, Wavelength=254 nm (ZLMZLM 2021-06-17 12-11-40\001-P1-B1-ZLM-B-DL.D)




Figure S27. The HPLC chart of rac-**4ze**

VWD1 A, Wavelength=254 nm (ZLMZLM 2021-06-17 12-32-30\001-P1-B2-ZLM-B-L.D)





Figure S28. The HPLC chart of **4ze**

tert-butyl (S)-(1-(phenanthridin-6-yl)-3-phenylpropan-2-yl)carbamate (4zf)



4zf was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as white solid (93.5 mg, 76%). Mp: 139-141°C. Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak ID column, *ee* = 93 % (HPLC: 210 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, *t_r* (major) = 13.998 min, *t_r* (min) = 12.732 min). $[\alpha]_D^{25} = +19.5$ (c 1.0, CH₂Cl₂). **¹H NMR** (500 MHz, CDCl₃): δ 8.63 (d, *J* = 8 Hz, 1H), 8.55 (d, *J* = 8 Hz, 1H), 8.17 (d, *J* = 8.5 Hz, 1H), 8.07 (d, *J* = 7Hz, 1H), 7.82 (t, *J* = 7.5 Hz, 1H), 7.76-7.72 (m, 1H), 7.67-7.62 (m, 2H), 7.33-7.24 (m, 5H), 5.58 (s, 1H), 4.52 (s, 1H), 3.58-3.54 (m, 1H), 3.49-3.45 (m, 1H), 3.18-3.16 (m, 1H), 3.03-2.99 (m, 1H), 1.34 (s, 9H); **¹³C NMR** (125 MHz, CDCl₃): δ 159.0, 155.5, 143.4, 138.6, 132.8, 130.5, 129.7, 129.6, 128.6, 128.4, 127.5, 126.6, 126.4, 126.1, 125.6, 123.7, 122.4, 122.0, 79.0, 51.7, 40.7, 38.7, 28.3. HRMS (ESI) for C₂₇H₂₉N₂O₂ [M+H]⁺: calcd 413.2224, found 413.2223.

Chiral HPLC Charts for 4zf:






Figure S29. The HPLC chart of rac-4zf



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	12.732	BV E	0.4365	142.64622	5.03466	3.4138
2	13.998	VB R	0.5297	4035.92822	117.80275	96.5862

Figure S30. The HPLC chart of **4zf**

tert-butyl (S)-(4-methyl-1-(phenanthridin-6-yl)pentan-2-yl)carbamate (4zg):



4zg was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as white solid (86.3 mg, 76%). Mp: 122-124 °C. Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak ID column, *ee* = 94 % (HPLC: 210 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, *t_r* (major) = 9.076 min, *t_r* (minor) = 6.309 min).

$[\alpha]_D^{25} = +41.0$ (c 1.0, CH₂Cl₂). **¹H NMR** (500 MHz, CDCl₃) δ 8.65 (d, *J* = 8 Hz, 1H), 8.56 (d, *J* = 8 Hz, 1H), 8.40 (d, *J* = 7 Hz, 1H), 8.14 (dd, *J*₁ = 8.1 Hz, *J*₂ = 0.8 Hz, 1H), 7.86-7.83 (m, 1H), 7.75-7.71 (m, 2H), 7.66-7.63 (m, 1H), 5.18 (d, *J* = 6.5 Hz, 1H), 4.35 (d, *J* = 4 Hz, 1H), 3.61-3.58 (m, 1H), 3.51-3.47 (m, 1H), 1.75 (d, *J* = 5.5 Hz, 1H), 1.62-1.57 (m, 1H), 1.49-1.43 (m, 1H), 1.32 (s, 9H), 0.93 (d, *J* = 7 Hz, 3H), 0.87 (d, *J* = 6.5 Hz, 3H); **¹³C NMR** (125 MHz, CDCl₃): δ 159.2, 155.6, 143.5, 132.8, 130.4, 129.8, 128.5, 127.5, 126.5, 126.3, 125.8, 123.7, 122.4, 121.9, 78.8, 48.7, 44.1, 41.3, 28.3, 25.1, 23.2, 22.1. HRMS (ESI) for C₂₄H₃₁N₂O₂ [M+H]⁺: calcd 379.2380, found 379.2383.

Chiral HPLC Charts for 4zg:




Figure S31. The HPLC chart of rac-**4zg**





Figure S32. The HPLC chart of **4zg**


***tert*-butyl (*R*)-3-(phenanthridin-6-ylmethyl)piperidine-1-carboxylate (**4zh**)**



4zh was isolated via column chromatography (eluent: DCM to PE/EA = 5/1) as colorless liquid (80.0 mg, 71%, 91% *ee*). Enantiomeric excess was established by HPLC analysis by using a Daicel Chiralpak ID column, *ee* = 91 % (HPLC: 210 nm, *n*-Hexane/isopropanol = 90/10, flow rate 0.5 mL/min, 30 °C, t_r (major) = 17.14 min, t_r (minor) = 10.82 min). $[\alpha]_D^{25} = +34.6$


(*c* 1.0, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃): δ 8.65 (d, *J* = 8.3 Hz, 1H), 8.55 (d, *J* = 8.1 Hz, 1H), 8.24 (d, *J* = 8.2 Hz, 1H), 8.13 (d, *J* = 8.1 Hz, 1H), 7.84 (t, *J* = 7.6 Hz, 1H), 4.19-3.94 (m, 2H), 3.35-2.23 (m, 2H), 2.84-2.79 (m, 2H), 2.28 (s, 1H), 2.04 (s, 1H), 1.84 (s, 1H), 1.65 (s, 1H), 1.47-1.34 (m, 10H); ¹³C NMR (125 MHz, CDCl₃): δ 159.9, 154.9, 143.6, 132.9, 130.3, 129.7, 128.6, 127.3, 126.4, 126.2, 125.5, 123.6, 122.5, 121.9, 79.2, 50.1, 44.4, 39.5, 36.1, 31.1, 28.3, 24.9. HRMS (ESI) for C₂₄H₂₉N₂O₂ [M+H]⁺: calcd 377.2224, found 377.2225.

Chiral HPLC Charts for **4zh**:



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.85	BB	0.4887	1934.6	59.6	49.997
2	17.33	BBA	1.2890	1934.9	22.4	50.003


Figure S33. The HPLC chart of rac-4zh



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	10.82	BB	0.4754	264.3	8.3	4.548
2	17.14	BBA	1.0951	5545.8	73.9	95.452

Figure S34. The HPLC chart of 4zh


3.4 3 mmol-scale synthesis of 4a



Procedure: To a flame-dried Schlenk tube was added **1a** (3 mmol, 538 mg), 4CzIPN (0.15 mmol, 118 mg) and Hantzsch ester (912 mg, 3.6 mmol). The tube was evacuated and refilled with N₂ for three times. A solution of aldehyde **2a** (13.5 mmol, 784 mg), amine **3b** (13.5 mmol, 1.37 g) in 1,4-dioxane (75.0 mL) was added under nitrogen atmosphere. The reaction mixture was irradiated at a distance of 3 cm from 15 W blue LED and stirred at 25 °C for 14 h. Upon completion, the reaction mixture was concentrated under vacuum and the residue was purified by column chromatography on silica gel (200-300 mesh), eluting with the indicated mixture of ethyl acetate (EA)/petroleum ether (PE) to give pure **4a** (484.7 mg, 73%).


4. Mechanistic Studies

4.1 Radical scavenging experiment.




The procedure is similar as the one described in the model reaction of **1a** and **2a** under the standard reaction conditions except the addition of 2.0 equivalents of TEMPO. Radical-scavenging experiment indicated the reaction was completely suppressed when 2.0 equiv. TEMPO was added into the reaction mixture.

4.2 Formation and detection of intermediate **6** when the reaction time was shortened to 4 h.




Characterization of **6**:

N,N-diethyl-1-(phenanthridin-6-yl)propan-1-amine (**6**)




6 was isolated via column chromatography (eluent: PE/EA = 10/1) as a colorless liquid (12.8 mg, 20%). ¹H NMR (400 MHz, CDCl₃): δ 8.79 (d, *J* = 8.2 Hz, 1H), 8.66 (d, *J* = 8.3 Hz, 1H), 8.59 (d, *J* = 8.2 Hz, 1H), 8.22 (dd, *J*₁ = 8.1 Hz, *J*₂ = 1.4 Hz, 1H), 7.84-7.80 (m, 1H), 7.76-7.72 (m, 1H), 7.70-7.64 (m, 2H), 4.56 (dd, *J*₁ = 10.1 Hz, *J*₂ = 3.9 Hz, 1H), 2.72-2.61 (m, 4H), 2.56-2.45 (m, 1H), 2.12-2.01 (m, 1H), 1.53-1.39 (m, 4H), 0.87 (t, *J* = 7.3 Hz, 3H), 0.74 (t, *J* = 7.3 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 160.8, 143.3, 133.0, 130.4, 129.8, 128.2, 127.3, 126.6, 126.4, 126.4, 123.8, 122.1, 121.8, 66.5, 53.4, 21.6, 20.1, 12.0, 11.8.

4.3 Probing experiment on possible reaction intermediate.




Procedure for the conversion of **6** to **4a**: To a 25 mL flame-dried Schlenk tube was added **6** (0.3 mmol), 4CzIPN (0.015 mmol). The tube was evacuated and refilled with N₂ for three times. 1,4-dioxane (7.5 mL) was added under nitrogen atmosphere. The reaction mixture was irradiated at a distance of 3 cm from 15 W blue LED and stirred at 25 °C for 14 h. Upon completion, the reaction mixture was concentrated under vacuum and the residue was purified by column chromatography on silica gel (200-300 mesh), eluting with the indicated mixture of ethyl acetate (EA)/petroleum ether (PE) to give **4a** (90%).



Procedure for the conversion of **7** to **8**: To a 25 mL flame-dried Schlenk tube was added **7** (0.3 mmol), 4CzIPN (0.015 mmol). The tube was evacuated and refilled with N₂ for three times. 1,4-dioxane (7.5 mL) was added under nitrogen atmosphere. The reaction mixture was irradiated at a distance of 3 cm from 15 W blue LED and stirred at 25 °C for 14 h. Upon completion, the reaction mixture was concentrated under vacuum and the residue was purified by column chromatography on silica gel (200-300 mesh), eluting with the indicated mixture of ethyl acetate (EA)/petroleum ether (PE) to give **8** (67%).

Characterization of **8**:

2-propylquinoline (8):




¹H NMR (500 MHz, CDCl₃): δ 8.08 (d, *J* = 8.4 Hz, 2H), 7.79 (d, *J* = 8.0 Hz, 1H), 7.70 (t, *J* = 8.4 Hz, 1H), 7.50 (t, *J* = 8.0 Hz, 1H), 7.31 (d, *J* = 8.4 Hz, 1H), 2.98 (t, *J* = 7.6 Hz, 2H), 1.92-1.83 (m, 2H), 1.04 (t, *J* = 7.2 Hz, 2H), 1.92-1.83 (m, 2H), 1.04 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ

162.9, 147.8, 136.3, 129.4, 128.8, 127.5, 126.7, 125.7, 121.4, 41.2, 23.3, 14.0. Its analytical data are


consistent with the documented data.²¹

4.4 Detection of byproduct 4a'




Characterization of $4a'$:

6-ethylphenanthridine ($4a'$)



¹H NMR (500 MHz, CDCl₃) δ 8.68 (d, *J* = 8.3 Hz, 2H), 8.55 (d, *J* = 7.0 Hz, 1H), 8.27 (d, *J* = 8.1 Hz, 1H), 8.13 (dd, *J*₁ = 8.1 Hz, *J*₂ = 1.0 Hz, 1H), 7.85-7.82 (m, 1H), 7.73-7.68 (m, 2H), 7.64-7.60 (m, 1H), 3.42 (t, *J* = 7.6 Hz, 2H), 1.52 (t, *J* = 7.6 Hz, 3H). Its analytical data are consistent with the documented data.²²

4.5 KIE experiment.



Procedure: To a 25 mL flame-dried Schlenk tube was added **1a** (26.9 mg, 0.15 mmol), **1a-d5** (27.6 mg, 0.15 mmol) 4CzIPN (11.8 mg, 0.015 mmol) and Hantzsch ester (91.2 mg, 0.36 mmol). The tube was evacuated and refilled with N₂ for three times. A solution of aldehyde **2a** (78.3 mg, 1.35 mmol), amine **3b** (136.0 mg, 1.35 mmol) in 1,4-dioxane (7.5 mL) was added under nitrogen atmosphere. The reaction mixture was irradiated at a distance of 3 cm from 15 W blue LED and stirred at 25 °C for 14 h. Upon completion, the reaction mixture was concentrated under vacuum and the residue was purified by column chromatography on silica gel (200-300 mesh), eluting with the indicated mixture of ethyl acetate (EA)/petroleum ether (PE) to give pure **4a** and **4a-d4** (31.4 mg, 47%). The *k_H/k_D* was calculated to be 1.0 according to the analysis of ¹H NMR spectrum of **4a** and **4a-d4**.





Figure S35. ^1H NMR spectrum of **4a** and **4a-d4** for KIE experiments.

4.6 Deuterium-labeling experiments







Figure S36. ^1H NMR spectrum for Deuterium-labeling experiments.

5. References



1. M. Tobisu, K. Koh, T. Furukawa and N. Chatani, *Angew. Chem. Int. Ed.*, 2012, **51**, 11363-11366.
2. J. Rong, L. Deng, P. Tan, C. Ni, Y. Gu and J. Hu, *Angew. Chem. Int. Ed.*, 2016, **55**, 2743-2747.
3. Q. Li, C.-Y. Zhou and C. Wang, *Org. Lett.*, 2022, **24**, 7654-7658.
4. P. López-Mendoza and L. D. Miranda, *Org. Biomol. Chem.*, 2020, **18**, 3487-3491.
5. Y. Liu, X.-L. Chen, X. -Y. Li, S.-S. Zhu, S.-J. Li, Y. Song, L.-B. Qu and B. Yu, *J. Am. Chem. Soc.*, 2021, **143**, 964-972.
6. Q. Wang, X. Dong, T. Xiao and L. Zhou, *Org. Lett.*, 2013, **15**, 4846-4849.
7. X. Tang, S. Song, C. Liu, R. Zhu and B. Zhang, *RSC Adv.*, 2015, **5**, 76363-76367.
8. A. García-Urricelqui, A. de Cózar, A. Mielgo and C. Palomo, *Chem. Eur. J.*, 2021, **27**, 2483-2492.
9. S. Jung, N. Fuchs, P. Johe, A. Wagner, E. Diehl, T. Yuliani, C. Zimmer, F. Barthels, R. A. Zimmermann, P. Klein, W. Waigel, J. Meyr, T. Opatz, S. Tenzer, U. Distler, H.-J. Räder, C. Kersten, B.

- Engels, U. A. Hellmich, J. Klein and T. Schirmeister, *J. Med. Chem.*, 2021, **64**, 12322-12358.
10. E. Brenner, R. M. Baldwin and G. Tamagnan, *Org. Lett.*, 2005, **7**, 937-939.
11. H. Guan, Q. Zhang, P. J. Walsh, J. Mao, *Angew. Chem. Int. Ed.*, 2020, **59**, 5172-5177.
12. T. Gerfaud, L. Neuville and J. Zhu, *Angew. Chem. Int. Ed.*, 2009, **48**, 572-577.
13. Z. Yang, F. Chen, S. Zhang, Y. He, N. Yang and Q.-H. Fan, *Org. Lett.*, 2017, **19**, 1458-1461.
14. A. Kishi, K. Moriyama and H. Togo, *J. Org. Chem.*, 2018, **83**, 11080-11088.
15. C. Tang, Y. Yuan and N. Jiao, *Org. Lett.*, 2015, **17**, 2206-2209.
16. B. K. Mehta, K. Yanagisawa, M. Shiro and H. Kotsuki, *Org. Lett.*, 2003, **5**, 1605-1608.
17. Y. Jaiswal, Y. Kumar, J. Pal, R. Subramanian and A. Kumar, *Chem. Commun.*, 2018, **54**, 7207-7210.
18. X.-Y. Zhang, W.-Z. Weng, H. Liang, H. Yang and B. Zhang, *Org. Lett.*, 2018, **20**, 4686-4690.
19. J.-C. Yang, J.-Y. Zhang, J.-J. Zhang, X.-H. Duan and L.-N. Guo, *J. Org. Chem.*, 2018, **83**, 1598-1605.
20. (a) T. Xiao, L. Li and L. Zhou, *J. Org. Chem.*, 2016, **81**, 7908-7916; (b) J. Qin, Z. Zhou, T. Cui, M. Hemming and E. Meggers, *Chem. Sci.*, 2019, **10**, 3202-3207.
21. Q. Wu, S. Han, X. Ren, H. Lu, J. Li, D. Zou, Y. Wu and Y. Wu, *Org. Lett.*, 2018, **20**, 6345-6348.
22. D.-S. Li, T. Liu, Y. Hong, C.-L. Cao, J. Wu and H.-P. Deng, *ACS Catal.*, 2022, **12**, 4473-4480.



6. Copies of ^1H and ^{13}C NMR spectra





200521
BHY-F-Pr CDCL3 0521





LYK-B3





LYK-B3





200623
BHY-F-NA CDC13 0623





200623
BHY-F-NA CDCI3 0623





LYK-B4





LYK-B4





LYK-B2





LYK-B2



LYK-B1





LYK-B1





8.654
8.643
8.636
8.625
8.495
8.479
8.148
8.146
8.132
8.130
7.882
7.876
7.862
7.857
7.735
7.732
7.718
7.704
7.702
7.653
7.650
7.636
7.622
7.620
7.606
7.601
7.588
7.583
7.572
7.567
7.276



200623
BHY-F-R2-4F CDC13 0623





200623
BHY-F-R2-4F CDCl₃ 0623





191022
JQF-NC1 CDCl3 1022





191024
JQF-NCL CDC13 1024





LYK-B5





LYK-B5





LYK-B6





LYK-B6





LYK-B7





LYK-B7




200619
BHY-F-benbingquan CDCL3 0619





200619
BHY-F-benbinguan CDCL3 0619









200522
BHY-F-Citronellal CDCL3 0522





ZJ
zlm-NC-R1-ZJ CDCl3 1216





ZJ
zlm-NC-ZJ CDCI3 0125





200723
zlm-NC-D CDCL3 0723





200728
zlm-NC-D CDCl3 0728





LYK-B8





LYK-B8




200909
zlm-PD-2 CDC13 0909






ML
zlm-PD-2 CDCl3 0129








200618
zlm-N-Boc-L-CHO CDCl₃ 0618








R2-4CH3
zlm-NC-R2-4CH3 CDCl3 0119








R2-4Br
zlm-NC-R2-4Br CDCl3 0130











201013
ZLM-NC-R2-4CN CDCI3 1013





R2-4CN
zlm-NC-R2-4CN CDCl3 1203





200708
zlm-NC-R2-5CF3 CDCl3 0708





200721
zlm-NC-R2-5CF3 CDCI3 0721




R1-4OCH3
zlm-NC-R1-4OMe CDCl3 0129





R1-4OCH3
zlm-NC-R1-4OMe CDCl3 0129








200721
zlm-NC-R1-4Cl CDCI3 0721






R1-4CF3
zlm-NC-R1-4CF3 CDCl3 0129







200708
zlm-NC-R2-5CF3 CDCl3 0708








200708
zlm-NC-R2-5CF3 CDCl3 0708






R1-3, 5CH3
zlm-NC-3,5-CH3 CDCl3 1203








R1-2OCH3
zlm-NC-R1-2OMe CDCl3 0130







200721
zlm-NC-J CDCl3 0721









200723
zlm-NC-B CDCL3 0723




200720
zlm-NC-BB CDCl3 0720





200723
zlm-NC-BB CDCL3 0723









200811
zlm-NC-L CDCl3 0811






200619
BHY-F-N-Boc-paiding CDCL3 0619




200619
BHY-F-N-Boc-paiding CDCL3 0619











8.093
8.072
7.799
7.779
7.719
7.698
7.677
7.518
7.498
7.478
7.325
7.304



3.000
2.981
2.961

1.920
1.901
1.882
1.863
1.844
1.826

1.062
1.044
1.025



S111

